FibroBiologics (FBLG) Jones Healthcare Seaside Summit 2024 summary

Leadership and expertise

• Executive team and board bring over 60 years of experience in operations, product rollout, and clinical trials.

• Scientific advisory board includes world leaders in stem cells, now focused on fibroblast research.

• Board members are active in biopharma, contributing to clinical and financial strategy.

Pipeline and clinical development

• Phase I/II trial for diabetic foot ulcers planned for Q1 2025, with multiple sclerosis and degenerative disc disease to follow.

• Holds over 150 issued and pending patents in fibroblast technology.

• Near-term focus is on developing clinical products for upcoming trials.

Market and scientific positioning

• Cell therapy, gene therapy, and immunotherapy seen as future cures for chronic diseases, not chemical compounds.

• Only public company focused on therapeutic use of fibroblasts for chronic disease management.

• Fibroblasts offer anti-inflammatory and immune modulation benefits, and are easier and cheaper to source than stem cells.